PDCD1 and non-small cell lung carcinoma: In particular, immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have become major pillars of systemic treatment for advanced NSCLC and are being increasingly applied in earlier stages of disease [1,4,5,6].